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Introduction: Lower respiratory tract infections are the fourth cause of death 
worldwide and pneumococcus is the leading cause of pneumonia. Nonetheless, 
existing pneumococcal vaccines are less effective against pneumonia than invasive 
diseases and serotype replacement is a major concern. Protein antigens could induce 
serotype-independent protection, and mucosal immunisation could offer local and 
systemic immune responses and induce protection against pneumococcal colonisation 
and lung infection. 
Areas covered: Immunity induced in the experimental human pneumococcal carriage  
model, approaches to address the physiological barriers to mucosal immunisation and 
improve delivery of the vaccine antigens, different strategies already tested for 
pneumococcal mucosal vaccination, including live recombinant bacteria, nanoparticles, 
bacterium-like particles and nanogels as well as, nasal, pulmonary, sublingual and oral 
routes of vaccination. 
Expert commentary: The most promising delivery systems are based on 
nanoparticles, bacterial-like particles or nanogels, which possess greater 
immunogenicity than the antigen alone and are considered safer than approaches 
based on living cells or toxoids. These particles can protect the antigen from 
degradation, eliminating the refrigeration need during storage and allowing the 
manufacture of dry powder formulations. They can also increase antigen uptake, 
control release of antigen and trigger innate immune responses. 
 
Keywords: Streptococcus pneumoniae, pneumococcal surface protein A, serotype-
independent pneumococcal vaccines, experimental human pneumococcal carriage, 
nanoparticles, bacterial-like particles, nanogels, live recombinant bacteria, outer 
membrane vesicles 
 
1. Streptococcus pneumoniae is the leading cause of lower respiratory tract 
infections 
Streptococcus pneumoniae, also known as pneumococcus, is a Gram-positive 
bacterium that colonises asymptomatically the nasopharynx of humans [1], but can 
also invade other niches and cause non-invasive diseases such as acute otitis media, 
sinusitis and non-bacteraemic community acquired pneumonia (CAP), and when 
pneumococcus invades normally sterile sites, it gives rise to the life-threating invasive 
pneumococcal diseases (IPD), such as bacteraemic pneumonia, empyema, meningitis 
and sepsis [2]. 
Studies performed by the Global Health Metrics point out lower respiratory tract 
infections (LRI) as the fourth cause of death worldwide and pneumococcus is 
estimated to be the leading cause of LRI mortality in children under 5-years old [3]. 
Nonetheless, a decrease in deaths caused by pneumococcal pneumonia was observed 
in children younger than 5 years, while an increase occurred among adults over 70 
years in the period 1990–2017 [3]. These two facts were related to the introduction of 
pneumococcal conjugate vaccines in universal children vaccination programs of 
several countries and to the serotype replacement phenomenon that is particularly 
important in adult populations [4,5]. 
 
2. Existing pneumococcal vaccines 
Capsular polysaccharide is the main S. pneumoniae virulence factor and the 
antigen for all currently available pneumococcal vaccines. Capsular polysaccharides 
are also the basis for classification of pneumococcus in more than 95 serotypes, each 
serotype corresponding to a chemical and immunologically distinct polysaccharide [6].  
There are two types of vaccines, both administered via the parenteral route: 23-
valent pneumococcal polysaccharide vaccine (PPV-23), and pneumococcal conjugate 
vaccines, PCV10 and PCV13, the valence corresponding to the number of 
polysaccharides from different serotypes included into vaccine formulation. As a T-cell 
independent antigen, polysaccharides can induce serotype-specific antibody, but no 
immunological memory [7]. Therefore, pneumococcal polysaccharides from prevalent 
serotypes were chemically conjugated to carrier proteins in order to be protective in 
children under 2-years-old [7,8]. Today, the World Health Organization (WHO) 
recommends the inclusion of PCVs in immunisation programmes worldwide for children 
under 5-years-old [9]. PPV23 is recommended for at risk population >2 years and 
adults >65 years of age and PCV13 has been adopted in some developed countries for 
immunisation of adults > 50 years old [8]. 
An important effect of PCV introduction in childhood vaccination programmes is 
the herd protection observed in non-vaccinated population [10]. Several studies have 
demonstrated the herd effect, resulting in the reduction of vaccine type diseases [11-
14]. Nevertheless, there is still a high level of global mortality and morbidity caused by 
IPD, owing to the limited serotype coverage of PCVs, which results in replacement of 
serotypes included in vaccines by non-vaccine serotypes [14-16]. It has been shown 
that PCV elicits antibody responses against the capsule of the serotypes included in 
the vaccine, reducing carriage prevalence and density by those serotypes [17-21]. 
Therefore, PCV alters the microbiota in the nasopharynx leaving a vacant niche that 
could be occupied by non-vaccine serotypes and other respiratory pathogens such as 
Staphylococcus aureus and nontypeable Haemophilus influenzae (NTHi), potentially 
increasing respiratory infections. Following the implementation of PCVs, studies in 
different settings have reported the increased incidence in carriage and IPD caused by 
non-vaccine serotypes, indicating serotype replacement [22-32]. The serotype 
replacement mitigates the benefits of vaccination and has compelled pharmaceutical 
companies to develop higher-valency PCVs [33-36]. In addition, several initiatives are 
being directed to the development serotype-independent vaccines [37-41], including 
the addition of pneumococcal proteins to PCV formulations [42-44]. 
As mentioned, other pathogenic bacteria could replace the niche previously 
occupied by vaccine type serotypes. Randomized controlled trials and observational 
studies have reported an inverse association between S. pneumoniae with both H. 
influenzae (mainly NTHi) and S. aureus after PCV vaccination [45-49]. Both S. aureus 
and NTHi have been found significantly increased in PCV-vaccinees, specially causing 
episodes of acute otitis media [49-52]. Other studies conducted in South Africa [53], the 
US [54] and Greenland [55] have reported declined of H. influenzae and S. aureus 
carriage in PCV vaccinees.  
Novel vaccine strategies could solve issues regarding serotype replacement 
and could potentially increase protection against pneumococcal diseases; however, 
there will be a need for disease surveillance to monitor their effect over respiratory 
infections caused by other pathogenic bacteria.  
 
3. Effectiveness of current pneumococcal vaccines against pneumonia 
Pneumonia can be caused by viruses, bacteria, or fungi [56].
Recent data have demonstrated that the aetiology of pneumonia is not yet well 
established and studies are strongly influenced by factors as high sensitivity and low 
specificity of case definition, prior antibiotic treatment, access to healthcare, specimens 
collected from sites distant from the lungs, presence of multiple potential pathogens in 
the specimens collected, underrepresentation of fatal cases and bias related to the 
identification methods [57]. Nonetheless, S. pneumoniae is recognized as the main 
cause of bacterial pneumonia, followed by H. influenzae, while respiratory syncytial 
virus is the most common viral cause of pneumonia [3]. Also, relationship between 
previous virus infection and predisposition to bacterial infection has been reported [58]. 
Vaccine probe studies have contributed to point out pneumococcus and H. influenzae 
as important causes of pneumonia [57]. 
 Despite the difficulties to attribute an unequivocal aetiology to pneumonia, 
association between the introduction of pneumococcal vaccines and the reduction of 
mortality among children younger than 5 years of age was observed, but an increase 
among older adults was also reported [3]. Although case definition and methodologies 
vary, recent studies demonstrated that PCVs provide protection against CAP in 
children, especially for severe cases, after vaccine implementation, and that most non-
PCV13 serotypes presented lower invasiveness than vaccine serotypes [59-63]. 
 In adults, different meta-analysis studies could not consistently demonstrate 
PPV23 effectiveness [64-67], which is in accordance with the lack of induction of 
immunological memory by polysaccharide antigens [7]. However, the vaccine 
effectiveness of PPV23 for older adults remains controversial, as shown by a recent 
review about this subject [5]. Following the lack of unequivocal effectiveness of PPV23 
against pneumonia, the immunisation of adults with PCV13 was investigated in double-
blind placebo-controlled randomised clinical trial conducted in adults aged ≥65 years 
(CAPiTA study) in the Netherlands [68]. Post-hoc analyses showed lower incidence of 
CAP and a modest reduction in the hospitalisation rate and stay time among the 
vaccinated individuals [69,70], and similar results were observed in US [71,72], Italy 
[73], and Spain [74,75].  
 It is important to emphasize, however, that PCVs were less effective at 
preventing pneumococcal CAP compared to IPD and the effectiveness was obviously 
higher for vaccine type diseases than for non-vaccine type [68,76], indicating the 
potential for serotype replacement. Also, the high cost of PCVs hampers their 
introduction in low and middle-income countries [76]. Therefore, there is a need for 
novel approaches to fight pneumococcal pneumonia and mucosal immunisation is one 
of the most promising strategies to address this problem.  
 
4. Formulation approaches for mucosal immunisation against S. pneumoniae 
There are several important considerations for vaccination through the nasal 
and pulmonary routes, as they exhibit unique physiological properties. Numerous 
approaches have been reported for addressing the physiological challenges and 
improving delivery of the vaccine antigens (Figure 1). 
 
 4.1 Mucus layer 
The mucus layer is a major barrier encountered in both nasal and pulmonary 
delivery, as it forms a physical obstacle between the immune cells and the formulation 
[77]. In addition to functioning as a barrier, the mucociliary action of the surface results 
in clearance. For these reasons, formulations with mucoadhesive and mucopenetrative 
properties have been of interest [78]. Hydrophilic polymers such as carbopol, sodium 
alginate, pullulan, exhibit mucoadhesive effects through the formation of hydrogen 
bonds with the mucus [78,79]. Chitosan is another popular polymer that can interact 
with the mucus through ionic interactions, and also possesses additional immunogenic 
properties through opening of intercellular tight junctions and the activation of STING-
cGAS pathway [77,80]. The incorporation of such polymers has been shown to 
increase the retention time of the formulation at the mucosal site and postulated to 
promote greater local immune responses. In the peripheries of the lungs, the 
epithelium is covered by a surfactant layer which is composed predominantly of 
phospholipids [81]. Preparing formulations from these phospholipids is postulated to be 
beneficial for reducing the risk of toxicity, which is a recognised concern especially for 
particulate formulations [81]. 
 
 4.2 Antigen delivery and uptake 
Despite the acknowledgement that nasal and pulmonary immunisation can 
result in mucosal and systemic immune responses, the underlying physiology and 
mechanisms of how the formulations interact with the immune system are still not well 
understood [78]. The uncertainty of targets means that it is difficult to develop 
formulations which can target specific tissue or cell types.  
However, there are numerous non-specific targeting approaches that are known 
to improve immunostimulation, based on aspects such as improving uptake by antigen 
presenting cells and prolonged release of the antigen and/or adjuvant. It has been 
widely established that nanoparticle (NP) formulations exhibit these properties [82], and 
thus are of particular interest for mucosal vaccine formulations. Another consideration 
especially for particulate formulations is the ubiquitous presence of alveolar 
macrophages, which exhibit high activity and clear foreign material from the airways 
[81]. The clearance and the potential immune response by the alveolar macrophages 
should be considered for potential formulations. 
 
 4.3 Immune cell stimulation 
Serotype independent antigens, such as pneumococcal surface protein A 
(PspA), are generally protein or subunit based antigens, and are normally safer 
compared to the whole cell or viral vectors [83]. However, this low immunogenicity 
presents a challenge for formulating vaccines, and thus an adjuvant is generally 
required for inducing sufficient immune responses. Molecular adjuvants, such as 
cytokines, toll-like receptors agonists and nucleic acids, can be incorporated into the 
formulation with the antigen to improve immunogenicity [82]. Adjuvants can also be 
delivery vehicles, such as nanoparticles, emulsions and hydrogels [83]. Such 
formulations can improve the antigen exposure to the immune cells and also improve 
uptake by the antigen presenting cells. Although there are currently no approved 
intranasal or pulmonary protein vaccines, several preclinical formulations using 
serotype-independent antigens against S. pneumoniae have been explored.  
 
5. Human immunity induced in the lungs following nasal immunisation with live 
pneumococcus 
 The pneumococcus frequently colonises the human nasopharynx and this 
exposure elicits both humoral and cellular responses that have an immunising effect in 
humans [84,85]. An effective control of colonisation and an active alveolar 
macrophage-mediated immune response in the lung are thought to be essential for 
protection against pneumococcal pneumonia [86]. In humans, immunoglobulin 
deficiencies [87], co-infections [88] and polymorphisms in the IL-17A gene [89] 
increase the incidence of lung infection. These data suggest an important role for 
antibodies and Th17 CD4+ T cells in protection against pneumonia.   
 Experimental human colonisation studies have allowed to characterise the 
effects of colonisation with live S. pneumoniae bacteria in lung immunity. In the 
experimental human pneumococcal carriage (EHPC) model, healthy volunteers are 
intranasally inoculated with a pneumococcal serotype 6B strain leading to successful 
colonisation in approximately half of subjects [85,90]. In these studies, bronchoalveolar 
lavage fluid (BALF) is obtained from colonised and non-colonised volunteers to 
characterise lung mucosa immune responses. Colonisation induced by experimental 
inoculation increases the percentage of IL-17A+/TNF+ CD4+ memory T cell in BALF 
when comparing to non-colonised individuals after ex vivo stimulation with serotype 6B 
[84]. Additionally, production of IL-17A from lung cells stimulated with 6B 
pneumococcus is high in both colonised and non-colonised volunteers and this 
cytokine plays an important role improving alveolar macrophage-mediated S. 
pneumoniae killing [84]. EHPC has also demonstrated that intranasal inoculation with 
live bacteria in absence of colonisation increases antibody levels against 
pneumococcal proteins such as PspA [91].  
 More recent data using EHPC has shown that experimental colonisation, 
through micro-aspiration, boosts the innate lung immunity. It increases the 
opsonophagocytic capacity of alveolar macrophages against pneumococcus and the 
expression of pro-inflammatory cytokines such as IFN-γ and TNF-α [92]. This human 
data emphasises the benefits that nasal inoculation of live bacteria has upon lung 
immunity and as an attractive immunisation approach for pneumonia prevention. The 
induction of pneumococcal specific Th1/Th17 cellular and humoral responses and the 
non-specific boosting of innate lung immunity could potentially play a pivotal role in 
protection against pneumococcal pneumonia in humans.  
 
6. Immunity induced in the lungs following nasal immunisation with 
pneumococcal protein-based vaccines 
 Human and murine models have shown that mucosal exposure to 
pneumococcus elicits both mucosal and systemic humoral and cellular responses. 
Therefore, mucosal vaccination represents an attractive approach for immunisation as 
it mimics the natural route of pneumococcus infection. Intranasal immunisation with 
PspA has been largely studied showing promising results in protection against 
pneumococcal lung infection in animal models [93-98]. Early studies (Table 1) have 
shown that intranasal immunisation with PspA co-administered with a mucosal 
adjuvant such as cholera toxin subunit B (CTB) or non-toxic cholera toxin is protective 
against pneumococcal challenge models of pneumonia and induces serum IgA and 
IgG to PspA [93,94]. Current studies are focused in developing non-toxin-based nasal 
vaccine delivery systems to enhance the efficacy of PspA and other protein-based 
vaccine candidates against pulmonary infections [84]. 
 Other than describing different protein antigens used for mucosal immunisation, 
this review will focus on the different strategies already tested for mucosal vaccination, 
including live recombinant bacteria (Table 2), nanoparticles, bacterium-like particles 
and nanogels (Table 3). The protein antigens most commonly tested in mucosal 
immunisation are PspA and pneumococcal surface antigen A (PsaA) and they will be 
addressed here. Literature on mucosal immunisation includes not only nasal and 
pulmonary routes of vaccination, but also sublingual and oral routes. Finally, the use of 
non-protein antigens for mucosal immunisation against pneumococcal infections will be 
discussed. Since there is only a limited number of papers regarding mucosal 
formulations specifically for pneumococcus, we included everything there was in the 
databases about it, without limits on when the paper was written. 
 
7. Live recombinant Salmonella and Outer Membrane Vesicles for oral and nasal 
immunisation 
A live-attenuated strain of Salmonella enterica serovar Typhimurium expressing 
PspA was developed for use in oral immunisation of mice (Table 2). Oral immunisation 
induced anti-PspA IgG in serum and vaginal secretion, protecting mice against 
intraperitoneal lethal challenge with serotype 3 pneumococcal strain WU2 [99]. S. 
Typhimurium expressing PspA was also tested for protection against secondary 
pneumococcal pneumonia in mice. In this model, mice were intratracheally challenged 
with strain WU2 one week after intratracheal challenge with influenza virus PR8. A 
single oral dose protected mice from secondary pneumonia, resulting in attenuated 
pulmonary inflammation, reduction in bacterial loads in the lungs and increased 
survival. The immunisation induced anti-PspA IgG antibodies in serum and also IgA 
antibodies in serum and BALF [100]. 
A Phase I dose escalation trial was conducted to evaluate the safety and 
immunogenicity of three recombinant attenuated Salmonella enterica serovar Typhi 
vaccine vectors expressing PspA (Table 2). These strains were attenuated in vivo due 
to the absence of arabinose and expression of the antigen is delayed until after 
invasion of the host intestinal tissues. The group of volunteers receiving the highest 
dose (1010) through the oral route did not show increase in anti-PspA titers compared 
to baseline. The authors discuss that immunogenicity may have been limited due to 
pre-existing cross-reactive antibodies to S. Typhi [101]. 
Outer membrane vesicles (OMVs) from recombinant Salmonella have also 
been tested for mucosal vaccination against pneumococcal infections (Table 3). OMVs 
are formed by blebbing of the outer membrane of Gram-negative bacteria and contain 
periplasmic components. OMVs were purified from S. Typhimurium expressing PspA in 
the periplasm. Intranasal immunisation of mice with the OMVs elicited significant anti-
PspA IgG responses in the serum and weak mucosal IgA. Immunised mice showed 
complete protection against a low dose pneumococcal intraperitoneal challenge with 
serotype 3 strain WU2 and partial protection against high dose challenge [102]. OMVs 
from S. Typhimurium displaying fragments of PspA on the surface were used also to 
immunise mice intranasally. Protection against pneumococcal nasal colonisation with 
serotype 4 strain TIGR4 was observed in immunised mice, which was correlated with 
local production of antigen-specific IL-17A [103]. 
 
8. Live recombinant lactic acid bacteria and bacterium-like particles for nasal and 
sublingual immunisation  
Recombinant lactic acid bacteria (LAB) expressing pneumococcal antigens 
were also tested as vaccine (Table 2). LAB are microorganisms present in the 
gastrointestinal mucosa of healthy individuals that are widely used in dietary products 
and are generally recognized as safe. Lactococcus lactis, Lactobacillus casei, 
Lactobacillus plantarum, and Lactobacillus helveticus expressing PsaA directed to the 
cell wall were used in intranasal immunisation experiments in mice. Higher levels of 
specific serum IgG and mucosal IgA were detected in mice immunised with L. 
plantarum and L. helveticus. Vaccination with recombinant lactobacilli but not with 
recombinant L. lactis led to a decrease in S. pneumoniae recovery from nasal mucosa 
upon a colonization challenge with serotype 6B strain 0603. These results show that 
some Lactobacillus strains have intrinsic properties that make them suitable candidates 
for mucosal vaccination [104]. 
L. lactis expressing PspA intracellularly was used for intranasal immunisation of 
mice and induced anti-PspA IgG in serum (Table 2). Antibodies showed a balanced 
IgG1/IgG2a ratio, in contrast to immunisation with recombinant protein adjuvanted with 
alum inoculated subcutaneously. Immunisation with recombinant LAB afforded 
protection against lethal intraperitoneal and respiratory challenges against serotype 4 
strain TIGR4. Protection against respiratory challenge was higher than for vaccination 
with recombinant protein. Furthermore, animals immunised with live bacteria showed 
better protection than those inoculated with inactivated bacteria. Protection elicited by 
the recombinant LAB was associated with an IgG response with a Th1 profile [105]. 
Intranasal immunisation of mice with L. casei expressing PspA led to the induction of 
specific serum IgG but not of mucosal IgA. Partial protection against intraperitoneal 
challenge with serotype 3 strain A66.1 was observed [106]. 
Bacterium-like particles (BLPs) are based on acid-treated L. lactis, consisting of 
a peptidoglycan cell wall surrounding a single membrane [107]. The acid treatment 
degrades components inside the cell and within the cell wall, leaving a particle 
resembling a bacterial cell. They have similar shape and size to bacteria and can act 
as vaccine adjuvants to stimulate the immune system and enhance mucosal immunity 
(Table 3). PspA was incorporated onto the surface of these BLPs and intranasal 
immunisation of mice resulted not only in high levels of serum IgG antibodies, but also 
high levels of mucosal secretory IgA (SIgA) antibodies in the respiratory tract [108]. 
Moreover, mice were protected against fatal intranasal challenge with homologous and 
heterologous pneumococcal strains and bacterial load also decreased in the lungs, 
showing serotype independent protection [109]. Similar results were obtained when 
loading PspA and PsaA into BLPs [98]. The adjuvant effects of BLPs are well 
characterised, involving the activation of DCs through the TLR [107].  
 
9. Nanoparticles and nanogels 
 9.1 Nanoparticles 
Nanoparticle (NP) formulations such as polymeric NPs and liposomes have 
been shown to possess greater immunogenicity compared to the antigen alone [80]. 
This is thought to be due to mechanisms such as increased antigen uptake, controlled 
release of antigen and triggering the innate immune response [80]. There are several 
mucosal NP formulations which have been reported to exhibit protective effects against 
S. pneumoniae (Table 3). The mucosal-delivered formulations loaded with PspA have 
shown similar effects on the lung mucosa, inducing the production of PspA-specific 
antibodies in serum and BALF, reducing pneumococcal load and protecting against 
pneumococcal lethal challenge in murine models [96,110]. 
A NP formulation made from poly(glycerol adipate-co-ω-pentadecalactone) 
(PGA-co-PDL), with surface adsorbed PspA, resulted in increased antigen-specific IgG 
antibodies in the serum [96]. Challenge with the lethal pneumococcal serotype 3 strain 
ATCC6303 showed that the group immunised with the NP formulation exhibited lower 
bacterial load in the lungs, as well as increased survival (Table 3). The NP 
administered through the nose targeting the lungs also contributed to greater PspA 
specific IgG antibody titers in BALF than subcutaneous administration of PspA, which 
could have contributed to earlier control of the infection. These NPs were also 
formulated as larger spray-dried microparticles made from L-leucine, which confers 
several benefits, such as the possibility for direct inhalation into the lungs, as the 
particle size can be modified for optimal lung inhalation [111]. The dry powder form 
also improves stability, as no refrigeration is required during storage. Moreover, the 
formulation can be resuspended in an aqueous solvent for inhalation by nebulisation. 
These properties improve the practicality of the mucosal administered formulation. 
Another reported particulate formulation is the polysorbitol transporter (PST), 
which is made up of sorbitol diacrylate and low-molecular-weight polyethylenimine 
[110]. The polymer possesses osmotic properties that cause the cells to increase 
particle uptake through the caveolae-mediated pathway. Intranasal immunisation with 
PST formulation incorporating PspA induces DCs activation, associated with a Th2 or 
follicular helper T cell responses (Table 3). This resulted in generation of long-term 
memory antibody-producing cells and long-term protection against S. pneumoniae 
WU2. The mechanism is postulated to involve the induction of PPAR-γ expression in 
antigen presenting cells, which can control the Th2, or anti-inflammatory immune 
responses, as well as the generation of memory B cells [110].  
Chitosan NPs incorporating DNA encoding PsaA were also shown to protect 
mice against nasopharyngeal colonisation when administered intranasally [112]. The 
positive charge of the chitosan allows for complexation with the negatively charged 
DNA, and has been shown to be an effective mucosal gene carrier for other 
applications. Chitosan-DNA nanoparticles had an average size of 392 nm. Mice 
immunised intranasally with the nanoparticles showed higher anti-PsaA IgG both in 
serum and nasal washes when compared to animals inoculated with the naked DNA 
(Table 3). IgG response was characterized by a balanced IgG1/IgG2a ratio and by the 
secretion of IL-17A and IFN-γ by spleen cells [113].  
Chitosan nanoparticles containing encapsulated PsaA protein was also 
evaluated for nasal immunisation of mice (Table 3). Particles had an average size of 
691 nm and immunisation elicited higher IgG levels in the serum and higher IgA levels 
in nasal wash, BALF and middle ear lavage when compared to the naked protein. The 
immune response was characterized by the secretion of IL-17A, IL-4 and IFN-γ by 
spleen cells. Moreover, clearance of a serotype 14 strain in the middle ear and 
protection against intraperitoneal challenge with serotype 3 and serotype 14 strains 
were observed [114]. 
Although there are few applications of NPs against S. pneumoniae, these 
reported studies, in addition to numerous other studies investigating NP use against 
other pathogens, suggest that NP vaccines are a viable approach for mucosal 
immunisation [78]. 
 9.2 Nanogel 
In addition to NPs, a cationic cholesteryl pullulan (cCHP) nanogel that 
incorporates PspA has been investigated as a nasal vaccine formulation [115]. These 
gels are formed through hydrophobic interactions and can prolong the release of 
incorporated proteins, to improve immunogenicity.  
After immunisation with the nanogel, mice exhibited high levels of serum PspA-
specific IgG, and nasal and bronchial IgA responses, as well as systemic and mucosal 
Th17 responses (Table 3). Immunisation with this formulation protected mice against 
lethal challenge with S. pneumoniae Xen10 (derived from A66.1), which carries 
homologous PspA, as well as against serotype 3 strain 3JYP2670, which expresses 
heterologous PspA, and reduced colonisation and invasion in the upper and lower 
respiratory tracts by Xen10 [115]. 
A similar formulation with a cationic group-modified cCHP nanogel was tested 
to improve efficacy in macaques and shown to be effectively delivered to the nasal 
mucosa, being retained in the nasal tissues for up to 6 hours (Table 3). Serum IgG and 
mucosal IgA responses were observed. In addition, no PspA was found in the olfactory 
bulbs or the central nervous system, suggesting that the nanogel is safe and does not 
cause unnecessary trafficking of the antigen to vulnerable areas which may lead to 
unwanted consequences. Moreover, serum from immunised macaques passively 
protected mice from an intravenous lethal challenge with strains Xen10 and 3JYP2670. 
Cellular immune response was characterized by the secretion of Th2 and Th17 
cytokines by CD4+T cells [116].  
 
10. Mucosal immunisation with non-protein antigen: phosphorylcholine, cell wall 
polysaccharide and capsular polysaccharide 
Non-protein antigens have been tested as mucosal vaccines against 
pneumococcal infections in the first attempts for mucosal immunisation (Table 1). 
Intranasal immunisation with phosphorylcholine conjugated to porcine thyroglobulin 
was shown to induce antibodies in serum and BALF and to protect mice against a 
lethal challenge with a serotype 3 strain [117]. Inactivated pneumococcal whole cell 
and cell wall polysaccharide given intranasally to mice with cholera toxin or CTB as 
adjuvant were also shown to increase resistance to nasopharyngeal colonisation by 
serotype 6B strain 0603 [118,119]. Anti-cell wall polysaccharide serum IgG antibodies 
were predominantly directed against the phosphorylcholine component. Protection was 
shown to be independent of antibodies, but dependent on CD4+T cells and IL-17A. The 
immunisation strategy also protected in a model of fatal aspiration pneumonia by 
serotype 3 strain WU2 [119]. 
Capsular polysaccharides have also been used for mucosal immunisation. 
Serotype 1 and 3-tetanus toxoid conjugate vaccines were used for intranasal 
immunisation of mice with the adjuvant RhinoVax (Table 1). The adjuvant formulation is 
based on caprylic-capric glycerides dissolved in polysorbate 20 and water. Serum IgG 
and IgA response was observed for serotype 1 and immunised mice showed lower 
bacterial loads after 24 hours after challenge with serotype 1 strain 6301. Lower serum 
IgG levels were observed for serotype 3. Nevertheless, animals were protected against 
an intranasal lethal challenge with a serotype 3 strain ATCC6303 [120]. Nasal 
administration of these conjugate vaccines with LT-K63 and LT-R72 as adjuvants also 
induced protection against pneumococcal challenge [121]. 
Serotype 3 and serotype 14-CRM197 conjugate vaccines were tested in 
intranasal immunisation using IL-12 as adjuvant (Table 1). Specific IgG and IgM 
antibodies were detected in the serum of mice immunised with the serotype 3 
conjugate vaccine, whereas specific IgG, IgM and IgA antibodies were detected in the 
BALF. The use of IL-12 as adjuvant led to the increase in IgG2a antibodies when 
compared to animals immunised without adjuvant. When comparing immunisation with 
the conjugate vaccine plus IL-12, intramuscular vaccination led to higher survival after 
intraperitoneal challenge with serotype 3 strain A66.1, whereas intranasal immunisation 
led to higher protection against nasopharyngeal colonisation challenge with a serotype 
14 strain. Protection against colonisation was shown to be dependent on IgA [122]. 
Finally, lung immunisation with PPV23 has also been reported in humans 
(Table 1). Alveolar and bronchial immunisation with PPS23 using a nebulizer was 
compared to intramuscular administration in healthy human volunteers and also in 
patients with chronic obstructive pulmonary disease (COPD). PPV23 was shown to be 
safe to be administered by controlled inhalation and to induce serum antibody 
responses, albeit at lower levels when compared to intramuscular immunisation 
[123,124]. Another study reported negative results for pulmonary immunisation with 
PPV23 using a jet nebulizer.  Bronchoalveolar and serum antibody responses were 
compared in volunteers immunised after injected or inhaled PPV23. Increase in IgG 
and IgA in both serum and BALF of individuals was observed in inoculated via the 
intramuscular route, but not via the pulmonary route with alveolar deposition [125]. 
 
Expert opinion 
 Conjugate vaccines are highly effective against IPD, reduce nasopharyngeal 
colonisation and induce herd immunity. However, the protection is limited to the 
serotypes included in the formulations, leading to serotype replacement in the 
population. Moreover, the effectiveness of all current vaccines is much greater for IPD 
than community-acquired pneumonia, even when only vaccine type pneumonia is 
considered. Therefore, serotype-independent vaccines could deal with the serotype 
replacement and mucosal immunisation could fill the gap for pneumococcal pneumonia 
protection.  
 Several antigens are promising candidates for providing serotype-independent 
protection, and PspA is the most studied and has been applied to all strategies for 
mucosal immunisation: administered with mucosal adjuvants as CTB, expressed in live 
recombinant bacteria, expressed in Salmonella OMV, attached to BLP, and formulated 
in nanogels and nanoparticles (Tables 1-3). Hence, it is clear that PspA should be 
included in any new pneumococcal vaccine formulation. However, PspA is classified in 
3 families and 6 clades according to the amino acid sequence. Immunological cross-
reactivity occurs inside each PspA family and is higher among variants of the same 
clade. Consequently, new research should answer how many PspA variants from 
different clades should be included in a new vaccine, and recent works addressed this 
problem by generating hybrid molecules or formulating vaccines with a mix of different 
PspA variants. Furthermore, there is a question whether only PspA from different 
families will be sufficient to offer full protection and avoid a phenomenon similar to the 
serotype replacement. Thus, other pneumococcal antigens should be considered, for 
example, the immunisation with PsaA offered protection against nasopharyngeal 
colonisation, which should be useful for nasal vaccines, and antibodies against the 
pneumococcal toxin pneumolysin (Ply) could prevent tissue damage and local 
inflammation, so detoxified Ply mutants could enhance the protection offered by PspA, 
especially for lung immunisation. 
 The data presented here support the thought that intranasal immunisation with 
protein-based vaccines could provide a better protection against systemic and mucosal 
infections than parental immunisation. However, it is not clear yet whether these 
protein-based vaccines would induce the same protective responses in humans. 
However, it is evident from the presented data that the antigens must be formulated 
into some delivery system, since several works have shown that plain antigens are not 
able to induce an adequate immune response. Simple nebulisation or administration of 
antigens without adjuvants resulted in low or no immune response at all (Table 1), and 
the new approaches based on nanomaterials and bacterial-like particles seem to be 
tendency now (Table 3), which might be related to the easier quality control, when 
compared to live recombinant bacteria (Table 2), for example, and less concerns about 
safety in comparison to toxoid adjuvants such as CTB or LT mutants (Table 1).  
In addition to their adjuvant properties, other advantages are related to 
nanoparticle formulations. They can enhance antigen stability, direct the response to 
specific targets of the immune system, and allow preparation of dry-powder 
formulations that do not need cold-chain for storage, which should improve the access 
to vaccination. Moreover, mucosal administration offers the advantage of eliminating 
syringes and needles, removing the hazard of safe disposal and lowering the risk of 
blood-borne infections.    
 Some important questions could be addressed experimentally in the next years, 
for example, if there are differences between nasal and pulmonary routes, how to 
guarantee the administration of the intended dose and if mucosal vaccination should be 
an alternative or a complementary strategy to the existing parenteral pneumococcal 
vaccines. The uncertainty regarding the translation from animal models to humans for 
mucosal vaccines is an essential force driving toward clinical trials. Although clinical 
trials are extremely necessary, there are several difficulties to perform them, mainly in 
places with universal PCV vaccination. It will be critical to define end-points for these 
trials to show non-inferiority in relation to current vaccines, taking into account other 
parameters than IPD, such as colonisation, reduction of upper and lower respiratory 
tract infections, the absence of serotype replacement, and the impact on microbiota. It 
is noteworthy that the definition of the end-points should face the lack of consensus for 
pneumonia diagnosis. The experimental human pneumococcal carriage (EHPC) and/or 
other human models are interesting alternatives to answer some of these questions.  
 Pathways for licensing mucosal vaccines are not as clear as for parenteral 
vaccines. The case of an inactivated pneumococcal whole cell vaccine is a 
paradigmatic one. This vaccine was originally developed to be given via the intranasal 
route [118], but intramuscular administration was applied in the clinical trial [39]. The 
hindrance may be related to the fact that antibody mediated immune response, which 
is the one normally induced by parenteral administration, is very well understood. It is 
thought that neutralising antibodies bind to the antigen and block the infection. For 
pneumococcal vaccines, antibodies that can induce opsonophagocytosis are 
considered correlates of protection, while cellular immune responses and mucosal 
immunity have not yet unequivocal correlates of protection. 
 Finally, the upcoming mucosal vaccine preparations could address issues 
important for developing countries such as storage, stability and ease of administration, 




 The existing pneumococcal vaccines are less effective at preventing 
pneumococcal pneumonia compared to IPD and serotype replacement has 
been mitigating the benefits of vaccination. 
 Protein antigens could solve the serotype replacement problem and PspA is 
one of the most important antigens capable to induce protective immune 
response. 
 Generation of local immune response could offer protection against 
pneumococcal colonisation and lung infection. 
 In order to be administered into the lungs or intranasally, proteins have to be 
formulated in an adequate delivery system.  
 The most promising delivery systems for mucosal administration are based on 
nanoparticles, bacterial-like particles or nanogels, as these formulations 
possess greater immunogenicity compared to the antigen alone and are 
considered safer than approaches based on living cells and adjuvanted with 
toxoids. 
 The particles can protect the antigen from degradation, increase antigen 
uptake, control release of antigen and trigger innate immune responses. 
 Particles can also stabilise the antigen, allowing the manufacture of dry powder 
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Figure 1: Overview of the barriers associated with vaccine delivery at the mucosal 
surface after administration through the nasal or pulmonary route. Common strategies 
for improving the vaccine efficacy through overcoming identified barriers have been 
listed. 
  
Table 1 – Early attempts for mucosal immunisation against pneumococcal diseases: 
use of pneumococcal antigens with adjuvants 
Vaccine candidate Administration 
route 
Model Protection  Reference 
PspA + CTBa nasal murine protection against fatal intratracheal and 
intravenous challenges  
Reduction of pneumococcal load in nasal 
wash 
[93] 
PspA + nontoxic CTAb nasal murine higher protection against fatal 
intravenous challenge than with native 
CTc 
[94] 
PS1-TTd and PS3-TTe 
+ RhinoVaxf 
nasal murine protection against lung 
infection and bacteraemia caused by 
serotype 1 
80% survival after fatal intranasal 
challenge with serotype 3 
[120] 
PS1-TTd and PS3-DTg 
+ LT-K63h and LT-R72i 
nasal murine protection against lung 
infection and bacteraemia caused by 
serotype 1 
≥90% survival after fatal intranasal 
challenge with serotype 3 
[121] 
PS3-CRM197j and 
PS14-CRM197k + IL-12 
nasal murine lower survival after intraperitoneal 
challenge with serotype 3 strain than 
intramuscular immunisation 
reduction of nasopharyngeal 
colonisation after challenge with a 





nasal murine protection against lethal intraperitoneal 
challenge 
[117] 
inactivated whole cell nasal murine 
 
rat 
protection against nasopharyngeal 
colonisation 
reduced morbidity and mortality after 





CTBa or CTc 
nasal murine increase resistance to nasopharyngeal 
colonisation 
protection against fatal aspiration 
pneumonia 
[119] 




lower levels of serum antibodies when 
compared to intramuscular 
immunization 
[123,124] 
inhaled PPV23m pulmonary healthy human 
volunteers 
no increase of IgG and IgA in serum and 
BALFo 
[125] 
a CTB – cholera toxin B subunit;  b CTA -  cholera toxin A subunit; c CT – cholera toxin; d PS1-TT 
– pneumococcal polysaccharide from serotype 1 (PS1) conjugated to tetanus toxoid (TT); e 
PS3-TT – pneumococcal polysaccharide from serotype 3 (PS3) conjugated to TT; f RhinoVax – 
adjuvant formulation based on caprylic-capric glycerides dissolved in polysorbate 20 and water; 
g PS3-DT – PS3 conjugated to diphtheria toxoid (DT); h LT-K63 and i LT-R72 – mutants of heat-
labile enterotoxin (LT) of Escherichia coli; j PS3-CRM197 – PS3 conjugated to nontoxic mutant of 
CRM197 diphtheria toxin; k PS14-CRM197 – pneumococcal polysaccharide from serotype 14 
(PS14) conjugated to CRM197; m inhaled 23-valent pneumococcal polysaccharide vaccine 
(PPV23) contains no adjuvant; nCOPD – chronic obstructive pulmonary disease; o BALF – 
bronchoalveolar lavage fluid. 
Table 2 – Live recombinant vaccines for mucosal immunisation against pneumococcal 
diseases 
Vaccine candidate Administration 
route 


















no increase in anti-PspA titers  in 






nasal murine reduction of pneumococcal load 
in nasal wash after lactobacilli 
immunisation, but no reduction 
with L. lactis 
[104] 
L. lactis expressing PspA nasal murine protection against lethal 
intraperitoneal and respiratory 
challenges 
[105] 





Table 3 – New approaches for mucosal immunisation against pneumococcal diseases 
Vaccine candidate Administration 
route 
Model Protection  Reference 
Salmonella OMV-
PspA 
nasal murine complete protection against low 





nasal murine dose-dependent reduction of 




nasal murine no reduction of pneumococcal load 
in nasal tissue 
[103] 
BLP-PspA-PA fusionc nasal murine 80-90% survival after fatal 
challenge 
[98] 
BLP-PspA3-PA fusionc nasal murine 100% survival after fatal challenge [109] 
BLP-PspA2-PA + BLP-
PspA4-PA fusionsc 
nasal murine 100% survival after intranasal fatal 
challenge with 2 pneumococcal 
strains 
[108] 
Chitosan-psaA gene nasal murine reduction of nasopharyngeal 
colonisation 
[112] 
Chitosan-PsaA nasal murine clearance of pneumococcus from 
middle ear 
protection against intraperitoneal 
challenge 
[114] 
cCHP-PspAd nasal murine reduction of colonization and 
invasion in upper and lower 
respiratory tracts100% survival 
after fatal challenge 
[115] 
cCHP-PspAd nasal macaques passive immunisation protects 
mice from intravenous fatal 
challenge 
[116] 
PGA-co-PDL-PspAe pulmonary murine lower pneumococcal load in BALF 
67% survival after fatal challenge 
[96] 
PST-PspAf nasal murine 100% survival after fatal challenge [110] 
a α-helical coiled coil domains (α-1 and α-2) of PspA; b lactoferrin-binding domain (LFBD) and 
the Pro-rich region (PRR) of PspA; c fusion of PspA with the protein anchor (PA), C-terminus of 
lactococcal protein ACMA, which serves to attach the protein to BLP; d cationic cholesteryl 
pullulan (cCHP) nanogel; e PGA-co-PDL - poly(glycerol adipate-co-ω-pentadecalactone); f 
polysorbitol transporter (PST), which is made up of sorbitol diacrylate and low-molecular-weight 
polyethylenimine. 
